210 related articles for article (PubMed ID: 15203440)
1. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants.
Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson R; O'Neil P
Addict Biol; 2004 Mar; 9(1):59-65. PubMed ID: 15203440
[TBL] [Abstract][Full Text] [Related]
2. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants.
Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson RC
Addict Biol; 2004 Mar; 9(1):67-72. PubMed ID: 15203441
[TBL] [Abstract][Full Text] [Related]
3. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
4. Blood naltrexone levels over time following naltrexone implant.
Ngo HT; Arnold-Reed DE; Hansson RC; Tait RJ; Hulse GK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):23-8. PubMed ID: 17651881
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.
Hulse GK; Ngo HT; Tait RJ
Biol Psychiatry; 2010 Aug; 68(3):296-302. PubMed ID: 20537615
[TBL] [Abstract][Full Text] [Related]
6. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases.
Brewer C
Addict Biol; 2002 Jul; 7(3):321-3. PubMed ID: 12126492
[TBL] [Abstract][Full Text] [Related]
7. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
Ngo HT; Tait RJ; Hulse GK
Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134
[TBL] [Abstract][Full Text] [Related]
8. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
Foster J; Brewer C; Steele T
Addict Biol; 2003 Jun; 8(2):211-7. PubMed ID: 12850780
[TBL] [Abstract][Full Text] [Related]
9. Blood morphine levels in naltrexone-exposed compared to non-naltrexone-exposed fatal heroin overdoses.
Arnold-Reed DE; Hulse GK; Hansson RC; Murray SD; O'Neil G; Basso MR; Holman CD
Addict Biol; 2003 Sep; 8(3):343-50. PubMed ID: 13129837
[TBL] [Abstract][Full Text] [Related]
10. Determination of naltrexone and 6-beta-naltrexol in human plasma following implantation of naltrexone pellets using gas chromatography-mass spectrometry.
Toennes SW; Kauert GF; Grüsser SM; Jäkel W; Partecke G
J Pharm Biomed Anal; 2004 Apr; 35(1):169-76. PubMed ID: 15030891
[TBL] [Abstract][Full Text] [Related]
11. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
Tait RJ; Ngo HT; Hulse GK
J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
[TBL] [Abstract][Full Text] [Related]
12. Mental health outcomes following naltrexone implant treatment for heroin-dependence.
Ngo HT; Tait RJ; Arnold-Reed DE; Hulse GK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):605-12. PubMed ID: 17229510
[TBL] [Abstract][Full Text] [Related]
13. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users.
Hulse GK; Tait RJ
Addict Biol; 2003 Sep; 8(3):337-42. PubMed ID: 13129836
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Galloway GP; Koch M; Cello R; Smith DE
BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
[TBL] [Abstract][Full Text] [Related]
15. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
16. Naltrexone implant and blood naltrexone levels over pregnancy.
Hulse GK; Arnold-Reed DE; O'Neil G; Hansson RC
Aust N Z J Obstet Gynaecol; 2003 Oct; 43(5):386-8. PubMed ID: 14717319
[No Abstract] [Full Text] [Related]
17. Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.
Waal H; Frogopsahl G; Olsen L; Christophersen AS; Mørland J
Eur Addict Res; 2006; 12(3):138-44. PubMed ID: 16778434
[TBL] [Abstract][Full Text] [Related]
18. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.
McCaul ME; Wand GS; Rohde C; Lee SM
Alcohol Clin Exp Res; 2000 Sep; 24(9):1385-91. PubMed ID: 11003204
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.
Olsen L; Christophersen AS; Frogopsahl G; Waal H; Mørland J
Br J Clin Pharmacol; 2004 Aug; 58(2):219-22. PubMed ID: 15255807
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.
Turncliff RZ; Dunbar JL; Dong Q; Silverman BL; Ehrich EW; Dilzer SC; Lasseter KC
J Clin Pharmacol; 2005 Nov; 45(11):1259-67. PubMed ID: 16239359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
